Propofol Drug Incident: PGI’s Internal Panel Submits Report

Chandigarh : The high-level committee that was constituted by the Post Graduate Institute of Medical Education and Research (PGIMER) to investigate the speculations of the Propofol drug that led to the death of five patients in the institute, submitted its report to PGIMER director Dr Vivek Lal on Monday.

The committee chairman, Dr SK Gupta, head, department of neurosurgery, said that the committee had conducted several meetings to investigate the matter and the final report has been submitted to the director.

Since the drug was suspected to have killed five people who had undergone orthopaedic and neurosurgeries, a joint investigation team comprising drugs inspectors of the drugs control wing, Chandigarh, and Central Drugs Standards Control Organisation (CDSCO), Sub-Zone Baddi, drew samples of drug Propoven (Propofol injection) on September 2 and were sent to regional drugs testing laboratory, Chandigarh.

As per the CDSCO report, which was received on September 27, the drug has been declared as ‘not of standard quality’ by the laboratory, as it failed in sterility, free fatty acids, pH, Propofol dimer and bacteon test.

The PGI had also sent the samples to Panjab University and its own department of pharmacy for testing, results of which have been included in the internal committee’s report.

“The CDSCO reports were received by the UT health department and so far the PGIMER has not been given the sample testing report. We are waiting for the reports. Since I am out on an official visit, we will examine the committee’s report on Thursday and will take the necessary action”, said Dr Vivek Lal, adding that the UT health department’s samples report had confirmed our suspicion that the substandard drug was responsible for the deaths.

‘Notices already issued, CDSCO to take action on manufacturer’

UT health secretary Yashpal Garg said, “After receiving the reports, the notice was sent to Gupta Medical Store, emergency block, PGIMER, Chandigarh. Further on his disclosure, notice was sent to supplier wholesale firm M/s Shiv Amrit Chemist, Sarangpur village, Chandigarh. Further, notice was served to M/s Biovenice Criticure, sector 20, Panchkula as well. Further, M/s Nixi laboratory, manufacturing firm has been directed to recall all the batches of drug Propoven, including the batch of the drug found not of standard quality.”

“Now, the CDSCO will take the necessary action against the manufacturer,” he added.

  • Related Posts

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India